The optimum dose and mode of administration of luteinizing hormone releasing hormone analogue in in-vitro fertilization: a comparison of three regimens

Three regimens for administration of the luteinizing hormone releasing hormone analogue (LHRHa), buserelin, were compared in terms of pituitary down-regulation prior to ovarian stimulation for in-vitro fertilization (IVF). Thirtythree patients who had failed to conceive in previous IVF cycles were r...

Full description

Saved in:
Bibliographic Details
Published in:Human reproduction (Oxford) 1991-11, Vol.6 (10), p.1370-1372
Main Authors: Wren, marie, Tan, Seang Lin, Waterstone, John, Parsons, John
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Birth control
Buserelin - administration & dosage
dose
Dose-Response Relationship, Drug
Drug Administration Routes
Female
Fertilization in Vitro
Gynecology. Andrology. Obstetrics
Humans
IVF
LHRHa
Medical sciences
mode of administration
Sterility. Assisted procreation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three regimens for administration of the luteinizing hormone releasing hormone analogue (LHRHa), buserelin, were compared in terms of pituitary down-regulation prior to ovarian stimulation for in-vitro fertilization (IVF). Thirtythree patients who had failed to conceive in previous IVF cycles were randomly divided into three groups. Patients in Group I (n = 11) received intranasal (i.n.) buserelin 200 μg four hourly for 21 days; patients in Group II (n = 11) received subcutaneous (s.c.) buserelin 500 μg twice a day for 7 days, followed by 500 μg daily for 14 days; patients in gruup III (n = 11) recived (s.c.) buserelin 500 μg three times a day for 7 days. In all three groups administration of buserelin was continued until serum oestradiol levels were
ISSN:0268-1161
1460-2350
DOI:10.1093/oxfordjournals.humrep.a137270